Biochips as Pathways to Drug Discovery (Drug Discovery Series) Review

Average Reviews:

(More customer reviews)Features a wealth of useful information about a number of things relating to microarray technology and its utility in drug discovery. Thus, it hinges on the fact that this field is actively evolving at a rapid pace, and as the title suggests, is going to impact ( if not already ) the Pharmaceutical Industry by minimizing the failure rate of early stage drug developments in drug discovery.
There is so much info packed into this compilation that this review in no way can do it justice. But let me just say it offers an excellent selection of contributing authors providing fundamental reviews in areas of interest for those running a Core Facility, such as laboratory automation, quality control, and amplification stratagies. It also offers many good selections of case studies for Cancer Drug Discovery, ChIP-on-Chip, Multiplexed Platforms, Toxigenomics, and Malaria Antiparasitic Discovery, and Protein Arrays to name a few.
In particular, I enjoyed the coverage of the Industry as a sector with chapters discussing the evolution of the science itself, the platforms available, the future directions, and the market shares and trends of the companies involved. I would say one of strengths of this book lies in its ability to present the biological meaning of the concepts presented e.g. "the use of biochips for elucidating the mechansims of drug action" and "vaccine developments". The other great thing is that it covers the bleeding edge information of the field, so you are getting the most current stuff from those on the front-lines actively using, developing, and shaping the future direction of the field itself. I give it five stars without blinking an eye :)

Click Here to see more reviews about: Biochips as Pathways to Drug Discovery (Drug Discovery Series)

In the fiercely competitive pharmaceutical marketplace, your organization cannot afford to spend excess dollars developing drugs that will fail to get FDA approval or have profoundly poor characteristics. Biochips as Pathways to Drug Discovery takes a comprehensive look at how the industry faces these challenges, using new technologies such as biochips to reduce the cost of drug discovery and improve drug safety. The book explores the tools and skills required at each step of the discovery process when using biochips to determine biological outcomes.
The authors provide an in-depth review of the clinical and pharmacogenomic relevance of biochips, ChIP-chip assays, and high-throughput approaches. They discuss how biochips are used to develop biomarkers in the drug discovery process, primarily for gene expression profiling and Single Nucleotide Polymorphism (SNP) analysis. The book includes coverage of experimental theory, quality control, clinical laboratory sampling considerations, database concepts, industrial laboratory design, and the analysis of the resultant large data sets. It discusses the application of biochips to the study of malaria, toxicogenomics, and SNPs, as well as intellectual property and market overviews. The book concludes with a comprehensive overview of how these chips are employed from early target discovery through preclinical toxicology and on through to pharmacogenomic and proof of concept studies in humans.
Written in an easily accessible style, the breadth of coverage introduces the subject to those new to the field, while the depth of coverage forms a foundation for future work. The book gives you the knowledge required to leverage the technology into bona fide discoveries.
Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.

Click here for more information about Biochips as Pathways to Drug Discovery (Drug Discovery Series)